RBO 0618
Alternative Names: RBO-0618Latest Information Update: 19 Oct 2022
Price :
$50 *
At a glance
- Originator Rubedo Life Sciences
- Class Antifibrotics; Small molecules
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 19 Oct 2022 Discontinued for Chronic obstructive pulmonary disease in USA (unspecified route) (Rubedo Life Sciences website, October 2022)
- 19 Oct 2022 Preclinical trials in Idiopathic pulmonary fibrosis in USA (unspecified route) (Rubedo Life Sciences website, October 2022)
- 01 Jun 2021 Rubedo Life Sciences and Cedars-Sinai Medical Center collaborates for Idiopathic pulmonary fibrosis